<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39375202</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020-2023 versus 2016-2019 in a Nation-Wide Cohort Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-024-05733-y</ELocationID><Abstract><AbstractText>Although several studies have explored the geoepidemiology of autoimmune rheumatic diseases (ARD), trends of their frequency overtime are under-investigated. Herein, in a nation-wide study, we examine trends in the prevalence of various ARD over-time, taking also into account the Covid-19 pandemic. In this retrospective study in the entire Greek adult population (approximately 10.000.000 people), we searched the electronic prescription database of the e-Government Centre for Social Security Services using prespecified ICD-10 codes to capture all adult patients with Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Polymyalgia Rheumatica or Giant Cell Arteritis (PMR/GCA). Two sequential 4-year periods, namely 2016-2019 and 2020-2023 were compared. Prevalence of RA, PsA, AxSpA, SLE and SSc increased significantly during 2020-2023 compared to 2016-2019. This applies to both genders and to all age groups for RA, PsA and AxSpA, to female patients in SLE and SSc and to patients 18-39 years in SLE and ≥ 60 years in SSc. Overall, there was 47% increase in prevalence for AxSpA (0.100% in 2016-19 vs 0.147% in 2020-23), 36.5% for PsA (0.148% vs 0.202%), 20.6% for RA (0.467% vs 0.563%), 19% for SLE (0.137% vs 0.163%) and 13% for SSc (0.023% vs 0.026%). A 16.3% decrease was evident in GCA/PMR, limited to those ≥ 40 years old. In a nation-wide study we confirm that ARD prevalence increases over-time, whereas a contribution of Covid-19 pandemic to our results during 2020-2023, cannot be excluded. Additional human, medical and financial resources will be needed to cover the increased needs of ARD patients.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bournia</LastName><ForeName>Vasiliki-Kalliopi</ForeName><Initials>VK</Initials><Identifier Source="ORCID">0000-0002-2162-1362</Identifier><AffiliationInfo><Affiliation>First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology Programme, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fragoulis</LastName><ForeName>George E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0003-4932-7023</Identifier><AffiliationInfo><Affiliation>First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology Programme, National and Kapodistrian University of Athens Medical School, Athens, Greece. geofragoul@yahoo.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitrou</LastName><ForeName>Panagiota</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0008-7315-6918</Identifier><AffiliationInfo><Affiliation>Hellenic Republic Ministry of Health, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolakidis</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7364-4542</Identifier><AffiliationInfo><Affiliation>IDIKA SA - E-Government Centre for Social Security Services, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathioudakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0001-4422-1521</Identifier><AffiliationInfo><Affiliation>IDIKA SA - E-Government Centre for Social Security Services, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassilopoulos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2288-3863</Identifier><AffiliationInfo><Affiliation>Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Joint Academic Rheumatology Programme, National and Kapodistrian University of Athens Medical School, General Hospital of Athens "Hippokration", Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tektonidou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2238-0975</Identifier><AffiliationInfo><Affiliation>First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology Programme, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paraskevis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6167-7152</Identifier><AffiliationInfo><Affiliation>Department of Hygiene Epidemiology and Medical Statistics, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfikakis</LastName><ForeName>Petros P</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0001-5484-2930</Identifier><AffiliationInfo><Affiliation>First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology Programme, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammatory arthritis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">Systemic sclerosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375202</ArticleId><ArticleId IdType="doi">10.1007/s00296-024-05733-y</ArticleId><ArticleId IdType="pii">10.1007/s00296-024-05733-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cutolo M, Gotelli E (2023) Complex role of oestrogens in the risk and severity of rheumatoid arthritis in menopause. RMD Open. https://doi.org/10.1136/rmdopen-2023-003176</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2023-003176</ArticleId><ArticleId IdType="pubmed">37451812</ArticleId><ArticleId IdType="pmc">10351269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourley M, Miller FW (2007) Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 3(3):172–180. https://doi.org/10.1038/ncprheum0435</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncprheum0435</ArticleId><ArticleId IdType="pubmed">17334340</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller FW (2023) The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol 80:102266. https://doi.org/10.1016/j.coi.2022.102266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102266</ArticleId><ArticleId IdType="pubmed">36446151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavropoulou MP, Filippa MG, Panopoulos S, Spanos E, Spanos G, Tektonidou MG et al (2022) Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. Clin Exp Rheumatol 40(9):1789–1792. https://doi.org/10.55563/clinexprheumatol/x78tko</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/x78tko</ArticleId><ArticleId IdType="pubmed">35699085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavropoulou MP, Filippa MG, Vlachogiannis NI, Fragoulis GE, Laskari K, Mantzou A et al (2024) Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD Open. https://doi.org/10.1136/rmdopen-2023-003575</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2023-003575</ArticleId><ArticleId IdType="pubmed">38233075</ArticleId><ArticleId IdType="pmc">10806498</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis pp. (2022) The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 42(9):1493–1511. https://doi.org/10.1007/s00296-022-05136-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05136-x</ArticleId><ArticleId IdType="pubmed">35503130</ArticleId><ArticleId IdType="pmc">9063259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sfikakis pp. (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 11:180–210. https://doi.org/10.1159/000289205</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000289205</ArticleId><ArticleId IdType="pubmed">20173395</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN et al (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401(10391):1878–1890. https://doi.org/10.1016/S0140-6736(23)00457-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00457-9</ArticleId><ArticleId IdType="pubmed">37156255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A, Jeremias P, Matthias T (2015) The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis 3(4):151–155</Citation><ArticleIdList><ArticleId IdType="doi">10.12691/ijcd-3-4-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GC, Kaine J, Deodhar A (2020) Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum 50(4):687–694. https://doi.org/10.1016/j.semarthrit.2020.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.05.005</ArticleId><ArticleId IdType="pubmed">32521322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg IE, Sharma A, Turesson C, Mohammad AJ (2022) An update on polymyalgia rheumatica. J Intern Med 292(5):717–732. https://doi.org/10.1111/joim.13525</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13525</ArticleId><ArticleId IdType="pubmed">35612524</ArticleId><ArticleId IdType="pmc">9796644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G et al (2023) Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology (Oxford) 62(3):1047–56. https://doi.org/10.1093/rheumatology/keac422</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac422</ArticleId><ArticleId IdType="pubmed">35920774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Bournia VK, Sfikakis pp. (2022) Different systemic rheumatic diseases as risk factors for COVID-19-related mortality. Clin Rheumatol 41(6):1919–1923. https://doi.org/10.1007/s10067-022-06190-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06190-3</ArticleId><ArticleId IdType="pubmed">35499772</ArticleId><ArticleId IdType="pmc">9058744</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R et al (2019) Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken) 71(8):1084–91. https://doi.org/10.1002/acr.23743</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23743</ArticleId><ArticleId IdType="pubmed">30171803</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC et al (2022) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 74(12):2032–2041. https://doi.org/10.1002/art.42330</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42330</ArticleId><ArticleId IdType="pubmed">36054084</ArticleId><ArticleId IdType="pmc">10947520</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, Liao X, Lin Z, Liu W, Luo X, Zhan H et al (2023) Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019. Clin Rheumatol 42(9):2297–2309. https://doi.org/10.1007/s10067-023-06628-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06628-2</ArticleId><ArticleId IdType="pubmed">37294370</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDRA (2023) Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 5(10):e594–e610. https://doi.org/10.1016/S2665-9913(23)00211-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(23)00211-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T (2019) Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroenterol 25(18):2162–2176. https://doi.org/10.3748/wjg.v25.i18.2162</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i18.2162</ArticleId><ArticleId IdType="pubmed">31143068</ArticleId><ArticleId IdType="pmc">6526158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocque RJ, Beaudoin C, Ndjaboue R, Cameron L, Poirier-Bergeron L, Poulin-Rheault RA et al (2021) Health effects of climate change: an overview of systematic reviews. BMJ Open 11(6):e046333. https://doi.org/10.1136/bmjopen-2020-046333</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046333</ArticleId><ArticleId IdType="pubmed">34108165</ArticleId><ArticleId IdType="pmc">8191619</ArticleId></ArticleIdList></Reference><Reference><Citation>Baimukhamedov C, Togizbayev G, Mirakhmedova K, Mamasaidov A, Shukurova S (2024) Increasing autoimmune rheumatic diseases as a consequence of the COVID-19 pandemic: a hypothesis or fact? Int J Rheum Dis 27(1):e15011. https://doi.org/10.1111/1756-185X.15011</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.15011</ArticleId><ArticleId IdType="pubmed">38140787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ (2023) Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56:101783. https://doi.org/10.1016/j.eclinm.2022.101783</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101783</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId><ArticleId IdType="pmc">9830133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F et al (2023) Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol 42(10):2905–2914. https://doi.org/10.1007/s10067-023-06670-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06670-0</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId><ArticleId IdType="pmc">10497688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekaryssova D, Joshi M, Gupta L, Yessirkepov M, Gupta P, Zimba O et al (2022) Knowledge and perceptions of reactive arthritis diagnosis and management among healthcare workers during the COVID-19 pandemic: online survey. J Korean Med Sci 37(50):e355. https://doi.org/10.3346/jkms.2022.37.e355</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e355</ArticleId><ArticleId IdType="pubmed">36573387</ArticleId><ArticleId IdType="pmc">9792259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekaryssova D, Yessirkepov M, Zimba O, Gasparyan AY, Ahmed S (2022) Reactive arthritis before and after the onset of the COVID-19 pandemic. Clin Rheumatol 41(6):1641–1652. https://doi.org/10.1007/s10067-022-06120-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06120-3</ArticleId><ArticleId IdType="pubmed">35247132</ArticleId><ArticleId IdType="pmc">8898028</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed U, Subramanian A, Wraith DC, Lord JM, McGee K, Ghokale K et al (2023) Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. BMC Med 21(1):363. https://doi.org/10.1186/s12916-023-03049-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03049-5</ArticleId><ArticleId IdType="pubmed">37735654</ArticleId><ArticleId IdType="pmc">10512476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SM, Eun S, Ji S, Hong S, Lee CK, Yoo B et al (2023) Incidence of rheumatic diseases during the COVID-19 pandemic in South Korea. Korean J Intern Med 38(2):248–253. https://doi.org/10.3904/kjim.2022.135</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2022.135</ArticleId><ArticleId IdType="pubmed">36646989</ArticleId><ArticleId IdType="pmc">9993092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SH, Ju HJ, Han JH, Lee JH, Lee WS, Bae JM et al (2023) Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open 6(10):e2336120. https://doi.org/10.1001/jamanetworkopen.2023.36120</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.36120</ArticleId><ArticleId IdType="pubmed">37801317</ArticleId><ArticleId IdType="pmc">10559181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee B, Acharya T (2020) The COVID-19 pandemic and its effect on mental health in USA—a review with some coping strategies. Psychiatr Q 91(4):1135–1145. https://doi.org/10.1007/s11126-020-09836-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11126-020-09836-0</ArticleId><ArticleId IdType="pubmed">32829449</ArticleId><ArticleId IdType="pmc">7443176</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox L, Karantzas GC, Romano D, Feeney JA, Simpson JA (2022) One year on: what we have learned about the psychological effects of COVID-19 social restrictions: a meta-analysis. Curr Opin Psychol 46:101315. https://doi.org/10.1016/j.copsyc.2022.101315</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copsyc.2022.101315</ArticleId><ArticleId IdType="pubmed">35398753</ArticleId><ArticleId IdType="pmc">8907153</ArticleId></ArticleIdList></Reference><Reference><Citation>Makari G, Friedman R (2024) Collective trauma and commemoration—a moment of silence please. NEJM. https://doi.org/10.1056/NEJMp2405167</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2405167</ArticleId><ArticleId IdType="pubmed">39115087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A et al (2020) Nocebo-prone behaviour in patients with autoimmune rheumatic diseases during the COVID-19 Pandemic. Mediterr J Rheumatol 31(Suppl 2):288–294. https://doi.org/10.31138/mjr.31.3.288</Citation><ArticleIdList><ArticleId IdType="doi">10.31138/mjr.31.3.288</ArticleId><ArticleId IdType="pubmed">33196007</ArticleId><ArticleId IdType="pmc">7656135</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos C, Ferreira RJO, Pinho AM, Costa C, Fragoulis GE, Psarelis S et al (2023) Impact of COVID-19 on disease (self) management and well-being in people with Rheumatic or Musculoskeletal diseases across four European countries: a mixed methods study. ARP Rheumatol 2(3):237–246</Citation><ArticleIdList><ArticleId IdType="pubmed">37839032</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Fang F, Tomasson G, Arnberg FK, Mataix-Cols D, Fernandez de la Cruz L et al (2018) Association of stress-related disorders with subsequent autoimmune disease. JAMA 319(23):2388–2400. https://doi.org/10.1001/jama.2018.7028</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.7028</ArticleId><ArticleId IdType="pubmed">29922828</ArticleId><ArticleId IdType="pmc">6583688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CC, Chen CJ (2023) New-onset inflammatory arthritis after COVID-19 vaccination: a systematic review. Int J Rheum Dis 26(2):267–277. https://doi.org/10.1111/1756-185X.14482</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14482</ArticleId><ArticleId IdType="pubmed">36371629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mv P, Auanassova A, Yessirkepov M, Zimba O, Gasparyan AY, Kitas GD et al (2023) New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome. Clin Rheumatol 42(10):2761–2775. https://doi.org/10.1007/s10067-023-06694-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06694-6</ArticleId><ArticleId IdType="pubmed">37422611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Konstantonis G, Tektonidou MG et al (2024) Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study. Rheumatology (Oxford) 63(4):1130–8. https://doi.org/10.1093/rheumatology/kead354</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead354</ArticleId><ArticleId IdType="pubmed">37467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Bournia VK, Mavrea E, Evangelatos G, Fragiadaki K, Karamanakos A et al (2022) COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatol Int 42(1):31–39. https://doi.org/10.1007/s00296-021-05039-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-05039-3</ArticleId><ArticleId IdType="pubmed">34739573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Karamanakos A, Arida A, Bournia VK, Evangelatos G, Fanouriakis A et al (2022) Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD Open. https://doi.org/10.1136/rmdopen-2022-002279</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002279</ArticleId><ArticleId IdType="pubmed">36597974</ArticleId><ArticleId IdType="pmc">9730398</ArticleId></ArticleIdList></Reference><Reference><Citation>Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E et al (2022) Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis 81(7):1013–1016. https://doi.org/10.1136/annrheumdis-2021-221539</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221539</ArticleId><ArticleId IdType="pubmed">34758975</ArticleId></ArticleIdList></Reference><Reference><Citation>Papagoras C, Zioga N, Papadopoulos V, Gerolymatou N, Kalavri E, Bounos C et al (2023) Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol 42(12):3375–3385. https://doi.org/10.1007/s10067-023-06769-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06769-4</ArticleId><ArticleId IdType="pubmed">37731083</ArticleId><ArticleId IdType="pmc">10640401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G et al (2021) All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019. RMD Open. https://doi.org/10.1136/rmdopen-2021-001694</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001694</ArticleId><ArticleId IdType="pubmed">34728554</ArticleId><ArticleId IdType="pmc">8565571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>